Share
3,548 Posts.
lightbulb Created with Sketch. 152
clock Created with Sketch. 01/11/17
12:02
Share
Originally posted by dgoynich
↑
Hi Guys - sent email to WP - he responded pretty quick as he does. I've attached his prelim response regarding the 4C - to put it bluntly and in my opinion only - some minor over-reaction by a few. Always best to look deeper. Everyone has their own reason for investing though so there is no right or wrong - just lots of opinions. Hence as previous - Dyor and GLTAHHi Wayne Regarding 4C today – was perceived as underwhelming by a lot of investors – and large holders. I believe the issue arose from one simple tweet - “Breakout Sales”... There may be a lot of questions from investors about a perceived under-delivering. This is actually the right tone - as July 2017/ July 2016 delivered a 100% increase in ADAPT sales. We did have our record ADAPT sales for the quarter in the US (in spite of the fact that we lost a month due to the hurricanes taking out 2 of our 3 biggest states in Texas and Florida which went to zero) I know 3D, 4C medical, TAVR, Shaped Tissues are all potential game changers but for some, today it felt like CC isn't growing fast enough to meet your predictions and investor (over)expectations. I think this worth addressing as most investors believe in your capability to deliver – but the results seem as though CC uptake is VERY VERY slow and underwhelming. Are there any issues with CC that we don't know about? We will meet my 2020 forecast and we will be profitable on schedule. We should not really look at quarterlies in isolation - yearlies are the best way to judge the business as there are operational issues that arise in an early stage company like ours that will always change the trajectory at times. The global commercial medical space is a game of share of voice (Feet on the ground ) which we still need more in order to compete - no question that we would have more sales if I could afford more reps - but I have to balance both sides of the equation right now. Having said that we have seen this quarter (the first where the new campaign is out there) we have been getting sales in accounts where we didnt have them before and our clinical superiority story is resonating - share of voice and saturation does take time - but we are now definitely getting traction now. As always – your feedback sincerely appreciated. Salvation is closer than it appears, its obviously frustrating that we can deliver 110% growth in profit, 58% growth in revenues, and 25% decrease in costs at our FY and get zero lift in the SP, then deliver 2 separate TAVR patents and and funding package that does not dilute shareholders and a solid quarterly result and get smashed in the market. It does impact the motivation of the team who have been focused on the share price and shareholder returns via me as they are doing long hours and a great job with great progress. To see the SP take a hit was tough on them. Thanks - looking forward to the AGM !
Expand
Thanks David, you're doing a great job. we have been getting sales in accounts where we didn't have them before and our clinical superiority story is resonating - share of voice and saturation does take time - but we are now definitely getting traction now. Regards
(20min delay)